Specifically, gain-of-function genetic variants in the LPL gene region, and loss-of-function (LoF) variants in the genes encoding its known inhibitors angiopoietin-like 4 (ANGPTL4) and apolipoprotein CIII (APOC3) are associated with a lower risk of coronary artery disease (CAD)9–14. Here, ANGPTL4 is linked to coronary artery disorder.